Managed Care


Fewer new therapies expected for GI disorders by 2010

MANAGED CARE April 2006. © MediMedia USA
Managed Care Outlook

Fewer new therapies expected for GI disorders by 2010

MANAGED CARE April 2006. ©MediMedia USA

Will prescription drugs for gastrointestinal disorders go the way antihistamine medications did when the FDA approved a generic version of Claritin in 2002?

It would appear so, according to "Gastrointestinal Market Outlook to 2010," published by Business Insights, a research and business intelligence consulting company.

Gastroesophageal reflux disease and peptic ulcer disease are among the most highly prevalent diseases, but because of patent expirations over the next five years, this market is forecast to have increasing generic competition and a low level of product introductions through 2010.

Gastrointestinal tract disorders affect millions of people of all ages in all geographic regions, but pharmaceutical research and development strategies in this area have now shifted to therapies for Crohn's disease and agents for irritable bowel syndrome (IBS).

Leading gastrointestinal drugs in development

Source: The Gastrointestinal Market Outlook to 2010


4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015